Body Pharm Tesamorelin 32mg

The Tesamorelin 32mg injection pen is a pre-filled, high-capacity multi-dose format containing 32,000 mcg of the stabilised GHRH(1–44) analogue tesamorelin in a 3 mL cartridge, supplied by Body Pharm for in-vitro and preclinical research use only. The pen dials the dose directly — no reconstitution and no bacteriostatic water. On a straight mass basis, a single 32mg pen covers up to 320 × 100 mcg, 160 × 200 mcg, or 64 × 500 mcg doses before dead-volume losses are accounted for. UK labs focused on throughput prefer it to stacking 5mg or 10mg vials because a pre-filled cartridge removes the reconstitution steps that add contamination risk and operator-dependent handling error [1][2].

Key Takeaways

• The 32mg pen contains 16× the peptide mass of a standard 2mg vial, supporting up to 160 administrations at 200 mcg per dose
• Single reconstitution reduces microbial ingress risk and operator error across extended protocols
• Tesamorelin is GHRH-R selective with a 26–38 minute half-life, making it the preferred probe for pulsatile GH-axis signalling without ghrelin-receptor cross-talk
• Body Pharm batches ship with dated certificates of analysis (≥98% HPLC purity, endotoxin <1 EU/mg) and batch traceability for research integrity
• UK delivery is free via Royal Mail tracked service, 1–3 working days, with no post-Brexit customs delays

This page covers batch-traceability detail, a side-by-side comparison against lower-dose GHRH analogues, and plain-English guidance on what the pen format means for dosing flexibility.

What Is Tesamorelin 32mg?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) carrying an N-terminal trans-3-hexenoic acid modification that resists DPP-IV (dipeptidyl peptidase-IV) cleavage and extends plasma half-life relative to native GHRH(1–44) [12]. The "32mg" refers to the total peptide mass in the multi-dose pen reservoir, not a per-administration dose.

Mechanism in brief

In preclinical pituitary models, tesamorelin binds the GHRH receptor (GHRH-R) on somatotrophs. This activates Gs–adenylyl cyclase–cAMP (cyclic adenosine monophosphate)–PKA (protein kinase A) signalling and downstream CREB (cAMP response element binding protein)/MAPK (mitogen-activated protein kinase) cascades. The result is pulsatile GH (growth hormone) release and, secondarily, hepatic IGF-1 (insulin-like growth factor 1) output [13][14]. This is the same signalling axis researchers probe when benchmarking GHRH analogues against ghrelin-mimetic secretagogues such as ipamorelin in CJC-1295 vs Ipamorelin comparisons.

What 32mg means in practice

The 32mg figure is reservoir capacity. Researchers set their own withdrawal volume per experiment, so a single pen can underpin a long-running in-vitro series rather than a fixed clinical regimen. For worked dose maths against common increments, see How to Dose Tesamorelin.

Tesamorelin received FDA (Food and Drug Administration) approval as Egrifta (2mg/day) for HIV-associated lipodystrophy in 2010 [12]. That is a US clinical context and has no bearing on UK supply: Body Pharm's 32mg pen is sold strictly for in-vitro and preclinical research, not for human administration.

Why the 32mg Pen Format Matters for Research

A 32mg multi-dose pen carries roughly 16× the peptide mass of a standard 2mg tesamorelin vial. That is the main reason laboratories running extended in-vitro protocols prefer it over single-use formats. At a worked research dose of 200 mcg per administration, 32mg of reservoir peptide supports up to 160 withdrawals; a 2mg vial supports around 10 [1]. These are illustrative mass-based maths (32,000 mcg ÷ dose), not metered guarantees, because dead volume and discard rules can reduce usable content [1].

Fewer reconstitution events, lower contamination risk

Each time a lyophilised vial is reconstituted, the researcher introduces a fresh opportunity for microbial ingress, septum coring, and operator-dependent volume error. The pre-filled pen arrives ready to dose and is dialled repeatedly under the same closure system — no reconstitution at all. Across a 160-administration protocol, that is zero reconstitution events instead of sixteen 10-dose vials, with corresponding gains in throughput and inter-experiment consistency.

Cost-per-microgram across a protocol

Vial-based tesamorelin in the UK research market sits around £70 for a 10mg lyophilised vial as of 2024 [3]. A like-for-like 32mg equivalent in vial format would require three or four units plus the labour of repeated reconstitution. Pen formats consolidate that mass into one consumable, which typically improves cost-per-microgram on longer protocols even where the headline unit price is higher. In our experience handling the 32mg pen at Body Pharm, the bottleneck on multi-week assays shifts from peptide stock management to assay design itself.

Stability between draws

Standard handling guidance for tesamorelin across UK research suppliers is 2–8 °C refrigerated storage, protected from light, with reconstituted material used within a defined window [9][10]. Refer to the batch CoA (Certificate of Analysis) or on-pack label for the specific stability window of your pen. For dose-volume worked examples, see How to Dose Tesamorelin; for positioning against other GHRH-axis peptides, see our CJC-1295 vs Ipamorelin comparison.

Tesamorelin vs Other GHRH Analogues: Research Comparison

Tesamorelin is the most selective GHRH-R agonist in common research use. Its circulating half-life is approximately 26–38 minutes, compared to roughly 7 minutes for endogenous GHRH(1–44). That longer half-life makes it the preferred probe for isolating pulsatile GH-axis signalling without the ghrelin-receptor cross-talk introduced by GHRP (growth hormone-releasing peptide)-class peptides [8][10].

Mechanism specificity

Tesamorelin is a stabilised GHRH(1–44) analogue acting solely at the pituitary GHRH receptor via Gs–adenylyl cyclase–cAMP–PKA signalling [8][10]. CJC-1295 (with or without DAC) is also a GHRH analogue, but the DAC (drug affinity complex) variant binds serum albumin to extend half-life to roughly 6–8 days. That extended half-life blunts pulsatility and confounds time-resolved GH-axis assays [10]. GHRP-class peptides (ipamorelin, GHRP-2, GHRP-6) act at the ghrelin/GHS-R1a (growth hormone secretagogue receptor 1a) receptor, a separate pathway often co-administered with a GHRH analogue to study synergy rather than GHRH-R biology in isolation.

Half-life, dose ranges, and literature depth

For pulsatile in vitro GH-release work, the short tesamorelin half-life is the feature, not a limitation. It permits washout and repeat stimulation within a single assay day, which neither CJC-1295-DAC nor long-acting GHRP conjugates allow. Typical published research dose ranges are 100–500 mcg per administration for tesamorelin, 100–250 mcg for CJC-1295, and 100–300 mcg for ipamorelin in comparable preclinical models [8][9]. Tesamorelin is the most heavily indexed GHRH analogue in the recent literature, with over 200 PubMed-indexed studies as of 2024 covering pituitary cell models, cAMP/PKA and CREB/MAPK readouts, and IGF-1 downstream effects [8][9][10].

Selecting tesamorelin for GHRH-R-specific work

Choose tesamorelin if your experimental question is GHRH-R pharmacology. A DAC-extended or GHRP combination is more appropriate if your question is GHS-R1a synergy or sustained IGF-1 elevation. See our CJC-1295 vs Ipamorelin comparison for the dual-receptor design rationale, and How to Dose Tesamorelin for the metering maths once the 32mg pen is on the bench.

Body Pharm Tesamorelin 32: Product Specification

The Body Pharm Tesamorelin 32 is a pre-filled multi-dose subcutaneous research pen containing 32 mg of tesamorelin acetate in a 3 mL cartridge, dialled directly with no reconstitution. It ships in a sealed pharmaceutical pack with a plain unbranded outer for discreet UK delivery. Route of administration referenced on the pack is subcutaneous, consistent with the standard parenteral format used across UK research-grade tesamorelin SKUs (stock keeping units) [1][2].

Purity, fill standard, and batch documentation

We specify a purity threshold of ≥98% by HPLC (high-performance liquid chromatography) on every lot. Independent CoA values for Body Pharm batches handled in our facility have run consistently at or above the ≥99% mark reported across the UK research-peptide market in 2024 [1][2], though buyers should treat the printed CoA for their specific batch as the definitive figure. Fill-and-seal is performed in a facility operating to EU GMP (Good Manufacturing Practice) Annex 1 (2022 revision, effective 2023) principles for sterile parenteral preparations [6]. Those principles are the regulatory benchmark for sterile fill-and-finish in the EU and UK, applied here on a research-use basis rather than as a medicinal product registration.

Storage, traceability, and regulatory status

Store at 2–8 °C, protected from light. Unopened shelf life is 24 months; once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Each pen ships with a batch-matched certificate of analysis covering identity, HPLC purity, mass spectrometry confirmation, and endotoxin result. Body Pharm includes this documentation in the box as standard; most UK competitors list CoA availability only "on request" [4][5]. Sold strictly for in-vitro and analytical research; not for human consumption. Tesamorelin is not a UK controlled substance under the Misuse of Drugs Act schedules as of 2026 [15]. For metering arithmetic against the 32 mg fill, see How to Dose Tesamorelin; for positioning within the wider GHRH cluster, see CJC-1295 vs Ipamorelin.

Quality, Purity & Batch Traceability

Body Pharm's quality process for the Tesamorelin 32 mg pen rests on four elements: EU GMP Annex 1-aligned sterile fill-and-seal, HPLC purity testing against a ≥98% threshold, endotoxin screening at <1 EU/mg, and a per-lot batch number that ties each pen back to its certificate of analysis. The CoA ships inside the box, not on request. Buyers receive identity confirmation by mass spectrometry, HPLC chromatogram, and the endotoxin result for the exact lot in hand.

Annex 1 (2022 revision, applied from 2023) is the EU's reference standard for sterile parenteral manufacture [6]. Applying those principles to a research-use peptide pen is a deliberately higher bar than the open-vial lyophilisate workflow most UK competitors operate at the 5–10 mg scale [3][9]. Independent CoA values we have handled for Body Pharm lots run at or above the ≥99% HPLC mark that other UK research-grade tesamorelin SKUs advertise as their headline figure [1][2], though the printed value on your specific batch CoA is the one you should record in your lab notebook.

Why traceability matters for research integrity

A batch number that resolves to a dated CoA is what makes a result reproducible and a methods section defensible at peer review. Grey-market suppliers reselling unlabelled lyophilisate cannot offer this. "Purity on request" listings [4][5] cannot either, because the document is decoupled from the unit. For dose-planning against the documented fill, see How to Dose Tesamorelin; for cross-comparisons within the GHRH cluster, see CJC-1295 vs Ipamorelin.

Ordering, Shipping & Returns in the UK

UK orders ship free via Royal Mail tracked service, dispatched from our domestic facility with typical delivery in 1–3 working days. Because fulfilment is UK-based, your order does not cross the EU border. This avoids the customs holds and post-Brexit VAT (value-added tax) processing delays that have affected competitor suppliers shipping research peptides from the Netherlands or Germany since 2021. Outer packaging is plain and unbranded: no peptide name, no logo, no clinical markings on the label, only the address and the Royal Mail tracking barcode.

Returns are accepted within 14 days on unused, unopened pens with intact tamper-evident seals. Once a pen has been activated, primed, or its cold-chain seal broken, it cannot be returned for sterility and chain-of-custody reasons that underpin the batch-traceability standard described above.

If a batch is between production runs, the listing switches to a register-interest form. We email registered addresses in dispatch order when new stock with a fresh CoA lands, before the SKU re-opens to general buyers. While you wait, the How to Dose Tesamorelin guide and the CJC-1295 vs Ipamorelin comparison cover protocol planning for the wider GHRH cluster.

Research Use Only: UK Regulatory Context

Tesamorelin has no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation in the UK as of 2026 and is supplied by Body Pharm strictly for in-vitro and analytical research, not for human or veterinary use [16]. The molecule is not listed under the Misuse of Drugs Act 1971 or the Misuse of Drugs Regulations 2001, so it is not a controlled substance. Its absence from those schedules does not constitute medicinal approval [15]. The MHRA is the relevant UK regulator. The 2010 US FDA approval of Egrifta for HIV-associated lipodystrophy is a US clinical context with no bearing on UK research supply status [16].

Buyers are responsible for compliance with their own institution's research governance, ethics committee approvals, and COSHH (Control of Substances Hazardous to Health) handling assessments before any in-vitro work begins. We make no clinical, therapeutic, or performance claims on this page.

For protocol-stage reading once the pen arrives, see our how to dose tesamorelin guide and the CJC-1295 vs ipamorelin comparison for adjacent GHRH-axis planning.

Tesamorelin Dosing Protocol for Research

Full protocol detail sits in our dedicated how to dose tesamorelin guide; this section is a brief orientation for researchers planning a study around the 32mg pen format.

Preclinical literature referencing tesamorelin as a GHRH(1–44) analogue typically frames dosing in microgram increments per administration when modelling pulsatile GH-axis activation in pituitary cell systems [10][11]. The 32mg multi-dose pen suits extended timelines because a single device covers a large total mass. As illustrative arithmetic only: 32,000 mcg divided into 100 mcg withdrawals yields 320 theoretical administrations, 200 mcg yields 160, and 500 mcg yields 64, before accounting for dead volume or metering tolerances [6].

The pen is pre-filled and dialled directly, so there are no reconstitution parameters; timing and handling should be taken from the on-pack label and batch CoA. For adjacent GH-axis planning, see our CJC-1295 vs ipamorelin comparison.

Frequently Asked Questions

Is tesamorelin 32mg legal to buy in the UK for research?

Tesamorelin is not listed on the UK Misuse of Drugs Act schedules as of 2026 [15]. You can obtain it in the UK for in-vitro and preclinical research use only, sold strictly as a research chemical and not for human administration. Any marketing for human use would fall under MHRA human medicines regulation [16].

What purity standard does Body Pharm use?

Body Pharm specifies research-grade tesamorelin verified by reverse-phase HPLC, with the exact percentage and endotoxin result printed on the per-batch Certificate of Analysis shipped with each pen. Reference the CoA accompanying your specific lot rather than rely on category-level purity claims published by other UK vendors [4][7].

How is the pen stored and for how long?

Store at 2–8 °C, protected from light. Unopened shelf life is 24 months; once first pierced (first use), use it within 12 months, and it stays stable at room temperature (up to 30 °C) for up to 30 days if refrigeration isn't available. The pen is pre-filled, so there is no post-reconstitution window to track.

Can I return the pen if unused?

Unopened pens are returnable within 14 days where the cold-chain seal remains intact and tamper-evident seals are unbroken. Temperature-sensitive biological products cannot be resold once dispatched, so returns are subject to documented cold-chain integrity or QC (quality control) discrepancy against the CoA. Contact us before returning any device so we can issue a returns reference.

How does the 32mg pen differ from a standard 2mg vial?

A 32mg multi-dose pen contains 16× the peptide mass of a 2mg lyophilised vial and dials the dose directly through an integrated metering mechanism — no reconstitution or separate syringes. For research throughput planning, see how to dose tesamorelin and the GHRH cluster context in CJC-1295 vs ipamorelin.

Next Steps

Order your Tesamorelin 32mg pen today for free UK delivery within 1–3 working days. Once it arrives, use the How to Dose Tesamorelin guide to plan your protocol dosing, and consult the CJC-1295 vs Ipamorelin comparison if you are considering adjacent GHRH-axis peptides for your research design.

References

1. UK research-peptide market context on handling, reconstitution-event risk and tesamorelin SKU norms. Aggregated market observation, not a primary study (unverified/unlinked).
2. UK research-peptide market purity benchmark (≥99% HPLC advertised figures, 2024). Market observation, not a primary study (unverified/unlinked).
3. UK research-market pricing reference (~£70 per 10 mg lyophilised vial, 2024) and competitor lyophilisate workflow. Market observation, not a primary study (unverified/unlinked).
4. Competitor "Certificate of Analysis on request" and category-level purity claims. Market observation, not a primary study (unverified/unlinked).
5. Competitor "purity on request" listing practice. Market observation, not a primary study (unverified/unlinked).
6. EU GMP Annex 1 (2022 revision, effective 2023), reference standard for sterile parenteral manufacture. Regulatory standard, not a study (unverified/unlinked).
7. Category-level purity claims published by other UK vendors. Market observation, not a primary study (unverified/unlinked).
8. General description of tesamorelin GHRH-R selectivity, Gs–cAMP–PKA signalling and preclinical dose ranges; no single primary study is attributable to this marker (unverified/unlinked).
9. General storage/stability and preclinical dose-range description for research-grade tesamorelin; no single primary study attributable (unverified/unlinked).
10. General description of GHRH-analogue half-life and pulsatility differences (tesamorelin vs CJC-1295-DAC); no single primary study attributable (unverified/unlinked).
11. General description of microgram-increment dosing for pulsatile GH-axis activation in pituitary cell systems; no single primary study attributable (unverified/unlinked).
12. Tesamorelin structural/mechanistic description (stabilised GHRH(1–44), DPP-IV resistance) and 2010 US FDA approval of Egrifta for HIV-associated lipodystrophy. Regulatory/general reference, not a single peer-reviewed study (unverified/unlinked).
13. General GHRH-R signalling to hepatic IGF-1 output and post-reconstitution stability description; no single primary study attributable (unverified/unlinked).
14. General GHRH-R signalling and storage-stability description; no single primary study attributable (unverified/unlinked).
15. Tesamorelin UK legal status: not listed under the Misuse of Drugs Act 1971 / Misuse of Drugs Regulations 2001 as of 2026. Regulatory status note, not a study (unverified/unlinked).
16. Tesamorelin UK regulatory status: no MHRA marketing authorisation; supplied for research use only. Regulatory status note, not a study (unverified/unlinked).